Latest Advances

  • Condition: Therapy-Related Myeloid Neoplasms
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Allogeneic Stem Cell Transplantation
  • Number of Patients: 12169
  • Published —
This study tested the safety and efficacy of using allogeneic stem cell transplantation to treat patients with therapy-related myeloid neoplasms.
  • Condition: Myelodysplastic Syndromes
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan
  • Number of Patients: 215
  • Published —
The study researched the outcomes of allogenic hematopoietic stem cell transplantation with Fludarabine/Treosulfan for patients with myelodysplastic syndromes.
  • Condition: Patients with Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN)
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation (allo-HSCT)
  • Number of Patients: 48
  • Published —
This study assessed the effectiveness of a new conditioning regimen comprising decitabine (Dec), busulfan (Bu), cyclophosphamide (Cy), fludarabine (Flu), and cytarabine (Ara-c) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN).
  • Condition: Myelodysplastic syndrome and chronic myelomonocytic leukemia
  • Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • Treatment Used: Decitabine-based conditioning regimen
  • Number of Patients: 22
  • Published —
The aim of the study was to assess the effectiveness and toxicity of decitabine-based conditioning regimen in patients with myelodysplastic syndrome (MDS), acute myeloid leukemia secondary to MDS (MDS-AML) or chronic myelomonocytic leukemia (CMML).
  • Condition: Acute Myeloid Leukemia, Myelodysplastic Syndromes Or Chronic Myelomonocytic Leukemia
  • Journal: Hematology (Amsterdam, Netherlands)
  • Treatment Used: Azacitidine Plus Lenalidomide
  • Number of Patients: 406
  • Published —
This review of the literature analyzed the effectiveness and adverse effects of Azacitidine Plus Lenalidomide (AZA plus LEN) for the treatment of patients with high-risk Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) Or Chronic Myelomonocytic Leukemia (CMML).
  • Condition: Refractory Myelodysplastic Syndrome
  • Journal: Leukemia research
  • Treatment Used: Glasdegib
  • Number of Patients: 35
  • Published —
This study evaluated the effectiveness and safety of the smoothened inhibitor glasdegib in hypomethylating agent (HMA)-failure myelodysplastic syndrome (MDS).
  • Condition: Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
  • Journal: Pathology oncology research : POR
  • Treatment Used: Azacitidine Therapy
  • Number of Patients: 83
  • Published —
The study researched the effects of azacitidine therapy for myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
  • Condition: Higher-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure of Hypomethylating Agents
  • Journal: American journal of hematology
  • Treatment Used: Omacetaxine Mepesuccinate (OM)
  • Number of Patients: 42
  • Published —
This study evaluated omacetaxine mepesuccinate (OM) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who had previously failed or been intolerant to hypomethylating agents (HMAs).
  • Condition: Relapse After Allogeneic Stem Cell Transplantation
  • Journal: Transplantation proceedings
  • Treatment Used: Azacitidine
  • Number of Patients: 28
  • Published —
The purpose of the study was to determine the effectiveness of Azacitidine in treating relapsed myeloid malignancy after allogeneic stem cell transplantation
  • Condition: Chronic Myelomonocytic Leukemia
  • Journal: Leukemia & lymphoma
  • Treatment Used: Lenalidomide
  • Number of Patients: 20
  • Published —
This study tested the safety and efficacy of using lenalidomide to treat a chronic, recurrent myelomonocytic leukemia.
Showing 1-10 of 10